Categories Earnings, Health Care

Arbutus Biopharma (ABUS): FY19 Earnings Snapshot

— Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a loss of $67.2 million or $1.21 per share last year.

— Total revenues edged up to $6.01 million from $5.9 million in 2018

— Research and development expenses were almost unchanged year-over-year at $57.6 million in fiscal 2019

— Achieved progress in a focused discovery effort on follow-on compounds for the current HBV pipeline

— On track to advance a next-generation oral HBV specific RNA-destabilizer with chemical scaffolds distinct from AB-452 through lead optimization

— Ended 2019 with $90.8 million in cash, cash equivalents and short-term investments

— Expects to utilize between $54 to $58 million of cash and investments to fund operations in 2020

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

American Express (AXP) Q2 2025 Earnings: Key financials and quarterly highlights

American Express Company (NYSE: AXP) reported its second quarter 2025 earnings results today. Consolidated total revenues, net of interest expense, were $17.9 billion, up 9% year-over-year, driven by increased Card

Netflix Q2 earnings jump on strong revenue growth; results beat estimates

Video streaming giant Netflix, Inc. (NASDAQ: NFLX) reported a sharp increase in revenue and profit for the second quarter of fiscal 2025. The numbers also beat analysts' estimates. The company's

Tesla Q2 Earnings Preview: Can energy gains offset EV demand Slump?

For Tesla Inc. (NASDAQ: TSLA), the new fiscal year has been quite challenging, with first-quarter sales falling to a three-year low amid production issues related to Model Y and increasing

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top